These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1317 related articles for article (PubMed ID: 31941643)
1. Source of cannabinoids: what is available, what is used, and where does it come from? Specchio N; Pietrafusa N; Cross HJ Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643 [TBL] [Abstract][Full Text] [Related]
2. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312 [TBL] [Abstract][Full Text] [Related]
3. Cannabinoids in treatment-resistant epilepsy: A review. O'Connell BK; Gloss D; Devinsky O Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044 [TBL] [Abstract][Full Text] [Related]
4. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. Reddy DS Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806 [TBL] [Abstract][Full Text] [Related]
6. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899 [TBL] [Abstract][Full Text] [Related]
7. Cannabis for the Treatment of Epilepsy: an Update. Gaston TE; Szaflarski JP Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563 [TBL] [Abstract][Full Text] [Related]
8. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373 [TBL] [Abstract][Full Text] [Related]
9. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329 [TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
11. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197 [TBL] [Abstract][Full Text] [Related]
12. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials. Nabbout R; Thiele EA Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540 [TBL] [Abstract][Full Text] [Related]
13. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Samanta D Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Franco V; Perucca E Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958 [TBL] [Abstract][Full Text] [Related]
15. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Golub V; Reddy DS Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006 [TBL] [Abstract][Full Text] [Related]
16. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. Chen JW; Borgelt LM; Blackmer AB Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221 [TBL] [Abstract][Full Text] [Related]
18. Use of cannabidiol in the treatment of epilepsy. Mazurkiewicz-Bełdzińska M; Zawadzka M Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946 [TBL] [Abstract][Full Text] [Related]
19. Epilepsy and cannabidiol: a guide to treatment. Arzimanoglou A; Brandl U; Cross JH; Gil-Nagel A; Lagae L; Landmark CJ; Specchio N; Nabbout R; Thiele EA; Gubbay O; The Cannabinoids International Experts Panel ; Epileptic Disord; 2020 Feb; 22(1):1-14. PubMed ID: 32096470 [TBL] [Abstract][Full Text] [Related]
20. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]